Effects of 18-kDa translocator protein knockdown on gene expression of glutamate receptors, transporters, and metabolism, and on cell viability affected by glutamate

Pharmacogenetics and Genomics

Volumn 22, Issue 8, 2012, Pages 606-619

  Veenman, Leo ^a   Bode, Julia ^b   Gaitner, Michal ^a   Caballero, Beatriz ^a   Pe'Er, Yelena ^a   Zeno, Sivan ^a   Kietz, Silke ^b   Kugler, Wilfried ^b   Lakomek, Max ^b   Gavish, Moshe ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

gene expression; glioblastoma; glutamate metabolism; glutamate receptor; glutamate transporter; microarray; mitochondrial 18 kDa translocator protein

Indexed keywords

AMPA RECEPTOR; GLUTAMATE RECEPTOR; GLUTAMATE TRANSPORTER; GLUTAMIC ACID; KAINIC ACID RECEPTOR; MITOCHONDRIAL 18 KDA TRANSLOCATOR PROTEIN; MITOCHONDRIAL PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

AMINO ACID METABOLISM; ANIMAL CELL; APOPTOSIS; ARTICLE; BRAIN DAMAGE; CARCINOGENESIS; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; DNA FRAGMENTATION; GENE EXPRESSION; GENE SILENCING; GENETIC MANIPULATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL;

RATTUS;

EID: 84863855985     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3283544531     Document Type: Article

References (90)

1. DeAngelis LM. Brain tumors. N Engl J Med 2001; 344:114-123.
2. Noch E, Khalili K. Molecular mechanisms of necrosis in glioblastoma: the role of glutamate excitotoxicity. Cancer Biol Ther 2009; 8:1791-1797.
3. Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol (Berl) 2005; 109:93-108. (Pubitemid 40287792)
4. Weisinger G, Kelly-Hershkovitz E, Veenman L, Spanier I, Leschiner S, Gavish M. Peripheral benzodiazepine receptor antisense knockout increases tumorigenicity of MA-10 Leydig cells in vivo and in vitro. Biochemistry 2004; 43:12315-12321. (Pubitemid 39280575)
5. Levin E, Premkumar A, Veenman L, Kugler W, Leschiner S, Spanier I, et al. The peripheral-type benzodiazepine receptor and tumorigenicity: isoquinoline binding protein (IBP) antisense knockdown in the C6 glioma cell line. Biochemistry 2005; 44:9924-9935. (Pubitemid 41033459)
6. Shoukrun R, Veenman L, Shandalov Y, Leschiner S, Spanier I, Karry R, et al. The 18-kDa translocator protein, formerly known as the peripheral-type benzodiazepine receptor, confers proapoptotic and antineoplastic effects in a human colorectal cancer cell line. Pharmacogenet Genomics 2008; 18:977-988.
7. Zeno S, Zaaroor M, Leschiner S, Veenman L, Gavish M. CoCl(2) induces apoptosis via the 18 kDa translocator protein in U118MG human glioblastoma cells. Biochemistry 2009; 48:4652-4661.
8. Cosenza-Nashat M, Zhao ML, Suh HS, Morgan J, Natividad R, Morgello S, Lee SC. Expression of the translocator protein of 18 kDa by microglia, macrophages and astrocytes based on immunohistochemical localization in abnormal human brain. Neuropathol Appl Neurobiol 2009; 35:306-328.
9. Gras G, Chré tien F, Vallat-Decouvelaere AV, Le Pavec G, Porcheray F, Bossuet C, et al. Regulated expression of sodium-dependent glutamate transporters and synthetase: a neuroprotective role for activated microglia and macrophages in HIV infection? Brain Pathol 2003; 13:211-222. (Pubitemid 36460821)
10. Gras G, Porcheray F, Samah B, Leone C. The glutamate-glutamine cycle as an inducible, protective face of macrophage activation. J Leukoc Biol 2006; 80:1067-1075. (Pubitemid 44646312)
11. McNally L, Bhagwagar Z, Hannestad J. Inflammation, glutamate, and glia in depression: a literature review. CNS Spectr 2008; 13:501-510. (Pubitemid 351965454)
12. Gavish M, Bar-Ami S,Weizman R. The endocrine system and mitochondrial benzodiazepine receptors. Mol Cell Endocrinol 1992; 88:1-13.
13. Braestrup C, Squires RF. Specific benzodiazepine receptors in rat brain characterized by high-affinity (3H)diazepam binding. Proc Natl Acad Sci USA 1977; 74:3805-3809. (Pubitemid 8189972)
14. James ML, Selleri S, Kassiou M. Development of ligands for the peripheral benzodiazepine receptor. Curr Med Chem 2006; 13:1991-2001.
15. Veenman L, Gavish M. The peripheral-type benzodiazepine receptor and the cardiovascular system. Implications for drug development. Pharmacol Ther 2006; 110:503-524.
16. Veenman L, Gavish M. The role of 18 kDa mitochondrial translocator protein (TSPO) in programmed cell death, and effects of steroids on TSPO expression. Curr Mol Med 2012; 12:398-412.
17. Gavish M, Bachman I, Shoukrun R, Katz Y, Veenman L, Weisinger G, et al. Enigma of the peripheral benzodiazepine receptor. Pharmacol Rev 1999; 51:629-650.
18. Papadopoulos V, Baraldi M, Guilarte TR, Knudsen TB, Lacapere JJ, Lindemann P, et al. Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol Sci 2006; 27:402-409. (Pubitemid 44069585)
19. Scarf AM, Kassiou M. The translocator protein. J Nucl Med 2011; 52: 677-680.
20. Veenman L, Papadopoulos V, Gavish M. Channel-like functions of the 18-kDa translocator protein (TSPO): regulation of apoptosis and steroidogenesis as part of the host-defense response. Curr Pharm Des 2007; 13:2385-2405. (Pubitemid 47321571)
21. Veenman L, Alten J, Linnemannstons K, Shandalov Y, Zeno S, Lakomek M, et al. Potential involvement of F(0)F (1)-ATP(synth)ase and reactive oxygen species in apoptosis induction by the antineoplastic agent erucylphosphohomocholine in glioblastoma cell lines: a mechanism for induction of apoptosis via the 18 kDa mitochondrial translocator protein. Apoptosis 2010; 15:753-768.
22. Ricchelli F, Sileikyte J, Bernardi P. Shedding light on the mitochondrial permeability transition. Biochim Biophys Acta 2011; 1807:482-490.
23. Veenman L, Levin E,Weisinger G, Leschiner S, Spanier I, Snyder SH, et al. Peripheral-type benzodiazepine receptor density and in vitro tumorigenicity of glioma cell lines. Biochem Pharmacol 2004; 68:689-698. (Pubitemid 38953450)
24. Vlodavsky E, Soustiel JF. Immunohistochemical expression of peripheral benzodiazepine receptors in human astrocytomas and its correlation with grade of malignancy, proliferation, apoptosis and survival. J Neurooncol 2007; 81:1-7. (Pubitemid 44963983)
25. Kugler W, Veenman L, Shandalov Y, Leschiner S, Spanier I, Lakomek M, et al. Ligands of the mitochondrial 18 kDa translocator protein attenuate apoptosis of human glioblastoma cells exposed to erucylphosphohomocholine. Cell Oncol 2008; 30:435-450.
26. De Groot JF, Piao Y, Lu L, Fuller GN, Yung WK. Knockdown of GluR1 expression by RNA interference inhibits glioma proliferation. J Neurooncol 2008; 88:121-133.
27. Ishiuchi S. New roles of glutamate receptors in glias and gliomas. Brain Nerve 2009; 61:753-764.
28. Brocke KS, Staufner C, Luksch H, Geiger KD, Stepulak A, Marzahn J, et al. Glutamate receptors in pediatric tumors of the central nervous system. Cancer Biol Ther 2010; 9:455-468.
29. Meldrum BS. Glutamate as a neurotransmitter in the brain: review of physiology and pathology. J Nutr 2000; 130:1007S-1015S. (Pubitemid 30173635)
30. Savaskan NE, Seufert S, Hauke J, Trankle C, Eyupoglu IY, Hahnen E. Dissection of mitogenic and neurodegenerative actions of cystine and glutamate in malignant gliomas. Oncogene 2011; 30:43-53.
31. Savaskan NE, Heckel A, Hahnen E, Engelhorn T, Doerfler A, Ganslandt O, et al. Small interfering RNA-mediated xCT silencing in gliomas inhibits neurodegeneration and alleviates brain edema. Nat Med 2008; 14:629-632. (Pubitemid 351809547)
32. De Groot J, Sontheimer H. Glutamate and the biology of gliomas. Glia 2011; 59:1181-1189.
33. Savaskan NE, Eyupoglu IY. xCT modulation in gliomas: relevance to energy metabolism and tumor microenvironment normalization. Ann Anat 2010; 192:309-313.
34. Schunemann DP, Grivicich I, Regner A, Leal LF, de Araujo DR, Jotz GP, et al. Glutamate promotes cell growth by EGFR signaling on U-87MG human glioblastoma cell line. Pathol Oncol Res 2010; 16:285-293.
35. Zeno S, Veenman L, Katz Y, Bode J, Gavish M, Zaaroor M. The 18 kDa mitochondrial translocator protein (TSPO) prevents accumulation of protoporphyrin IX. A TSPO knockdown study. Curr Mol Med 2012; 12: 494-501.
36. Schroeder A, Mueller O, Stocker S, Salowsky R, Leiber M, Gassmann M, et al. The RIN: an RNA integrity number for assigning integrity values to RNA measurements. BMC Mol Biol 2006; 7:3.
37. Galli S, Jahn O, Hitt R, Hesse D, Opitz L, Plessmann U, et al. A new paradigm for MAPK: structural interactions of hERK1 with mitochondria in HeLa cells. PLoS ONE 2009; 4:e7541.
38. Henneke M, Diekmann S, Ohlenbusch A, Kaiser J, Engelbrecht V, Kohlschutter A, et al. RNASET2-deficient cystic leukoencephalopathy resembles congenital cytomegalovirus brain infection. Nat Genet 2009; 41:773-775.
39. Montag J, Hitt R, Opitz L, Schulz-Schaeffer WJ, Hunsmann G, Motzkus D. Upregulation of miRNA hsa-miR-342-3p in experimental and idiopathic prion disease. Mol Neurodegener 2009; 4:36.
40. Jung K, Grade M, Gaedcke J, Jo P, Opitz L, Becker H, et al. A new sensitivitypreferred strategy to build prediction rules for therapy response of cancer patients using gene expression data. Comput Methods Programs Biomed 2010; 100:132-139.
41. Drai D, Benjamini Y, Golani I. Statistical discrimination of natural modes of motion in rat exploratory behavior. J Neurosci Methods 2000; 96:119-131. (Pubitemid 30138057)
42. Klipper-Aurbach Y, Wasserman M, Braunspiegel-Weintrob N, Borstein D, Peleg S, Assa S, et al. Mathematical formulae for the prediction of the residual beta cell function during the first two years of disease in children and adolescents with insulin-dependent diabetes mellitus. Med Hypotheses 1995; 45:486-490.
43. Huang daW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009; 4:44-57.
44. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29:e45.
45. Laezza F, Wilding TJ, Sequeira S, Coussen F, Zhang XZ, Hill-Robinson R, et al. KRIP6: a novel BTB/kelch protein regulating function of kainate receptors. Mol Cell Neurosci 2007; 34:539-550. (Pubitemid 46483076)
46. Kennedy MB. Origin of PDZ (DHR, GLGF) domains. Trends Biochem Sci 1995; 20:350.
47. Trimbuch T, Beed P, Vogt J, Schuchmann S, Maier N, Kintscher M, et al. Synaptic PRG-1 modulates excitatory transmission via lipid phosphatemediated signaling. Cell 2009; 138:1222-1235.
48. Tokumitsu H, Hatano N, Tsuchiya M, Yurimoto S, Fujimoto T, Ohara N, et al. Identification and characterization of PRG-1 as a neuronal calmodulinbinding protein. Biochem J 2010; 431:81-91.
49. Kennedy MB. Signal transduction molecules at the glutamatergic postsynaptic membrane. Brain Res Brain Res Rev 1998; 26:243-257. (Pubitemid 28318080)
50. Koomoa DL, Go RC,Wester K, Bachmann AS. Expression profile of PRAF2 in the human brain and enrichment in synaptic vesicles. Neurosci Lett 2008; 436:171-176.
51. Borsics T, Lundberg E, Geerts D, Koomoa DL, Koster J, Wester K, et al. Subcellular distribution and expression of prenylated Rab acceptor 1 domain family, member 2 (PRAF2) in malignant glioma: influence on cell survival and migration. Cancer Sci 2010; 101:1624-1631.
52. Krzywanski DM, Dickinson DA, Iles KE,Wigley AF, Franklin CC, Liu RM, et al. Variable regulation of glutamate cysteine ligase subunit proteins affects glutathione biosynthesis in response to oxidative stress. Arch Biochem Biophys 2004; 423:116-125. (Pubitemid 38198221)
53. Berlicki L. Inhibitors of glutamine synthetase and their potential application in medicine. Mini Rev Med Chem 2008; 8:869-878.
54. Arun P, Madhavarao CN, Moffett JR, Namboodiri MA. Regulation of N-acetylaspartate and N-acetylaspartylglutamate biosynthesis by protein kinase activators. J Neurochem 2006; 98:2034-2042. (Pubitemid 44298264)
55. Thomas AG, Wozniak KM, Tsukamoto T, Calvin D, Wu Y, Rojas C, et al. Glutamate carboxypeptidase II (NAALADase) inhibition as a novel therapeutic strategy. Adv Exp Med Biol 2006; 576:327-337, discussion 61-63.
56. Durand P, Golinelli-Pimpaneau B, Mouilleron S, Badet B, Badet-Denisot MA. Highlights of glucosamine-6P synthase catalysis. Arch Biochem Biophys 2008; 474:302-317.
57. Gaitner M. Effect of traumatic brain injury and the glutamatergic system on peripheral benzodiazepine receptor expression [Research Thesis (Master of Science)]. Israel: Senate of the Technion-Israel Institute of Technology; 2004, submitted.
58. Maaser K, Sutter AP, Scherubl H. Mechanisms of mitochondrial apoptosis induced by peripheral benzodiazepine receptor ligands in human colorectal cancer cells. Biochem Biophys Res Commun 2005; 332: 646-652. (Pubitemid 40745163)
59. Veenman L, Shandalov Y, Gavish M. VDAC activation by the 18 kDa translocator protein (TSPO), implications for apoptosis. J Bioenerg Biomembr 2008; 40:199-205.
60. Bode J, Veenman L, Caballero B, Lakomek M, Kugler W, Gavish M. The kDa translocator protein influences angiogenesis, as well as aggressiveness, adhesion, migration, and proliferation of glioblastoma cells. Pharmacogenet Genomics 2012 [Epub ahead of print].
61. Ruff MR, Pert CB,Weber RJ,Wahl LM,Wahl SM, Paul SM. Benzodiazepine receptor-mediated chemotaxis of human monocytes. Science 1985; 229:1281-1283. (Pubitemid 15021682)
62. Finnerty M, Marczynski TJ, Amirault HJ, Urbancic M, Andersen BR. Benzodiazepines inhibit neutrophil chemotaxis and superoxide production in a stimulus dependent manner; PK-11195 antagonizes these effects. Immunopharmacology 1991; 22:185-193.
63. Galdiero F, Bentivoglio C, Nuzzo I, Ianniello R, Capasso C, Mattera S, et al. Effects of benzodiazepines on immunodeficiency and resistance in mice. Life Sci 1995; 57:2413-2423.
64. Sacerdote P, Panerai AE, Frattola L, Ferrarese C. Benzodiazepine-induced chemotaxis is impaired in monocytes from patients with generalized anxiety disorder. Psychoneuroendocrinology 1999; 24:243-249. (Pubitemid 29125354)
65. Marino F, Cattaneo S, Cosentino M, Rasini E, Di Grazia L, Fietta AM, et al. Diazepam stimulates migration and phagocytosis of human neutrophils: possible contribution of peripheral-type benzodiazepine receptors and intracellular calcium. Pharmacology 2001; 63:42-49. (Pubitemid 32623460)
66. Lazzarini R, Sakai M, Costa-Pinto FA, Palermo-Neto J. Diazepam decreases leukocyte-endothelium interactions in situ. Immunopharmacol Immunotoxicol 2010; 32:402-409.
67. Ye ZC, Sontheimer H. Glioma cells release excitotoxic concentrations of glutamate. Cancer Res 1999; 59:4383-4391. (Pubitemid 29418758)
68. Sontheimer H. Malignant gliomas: perverting glutamate and ion homeostasis for selective advantage. Trends Neurosci 2003; 26:543-549. (Pubitemid 37176909)
69. Lyons SA, Chung WJ, Weaver AK, Ogunrinu T, Sontheimer H. Autocrine glutamate signaling promotes glioma cell invasion. Cancer Res 2007; 67:9463-9471. (Pubitemid 47535936)
70. Piao Y, Lu L, de Groot J. AMPA receptors promote perivascular glioma invasion via beta1 integrin-dependent adhesion to the extracellular matrix. Neuro Oncol 2009; 11:260-273.
71. Maniv I, Veenman L, Leschiner S, Spanier I, Marek I, Shterenberg A, et al. Novel TSPO ligands as neuroprotective agents. Abstracts of the 16th Annual Meeting of the Israel Society for Neuroscience (ISFN): 25-27 November 2007, Eilat, Israel, Neural Plasticity, 2007:73.
72. Fridkin E, Messer E, Leschiner S, Boginya A, Dutta B, Marek I, et al. TSPO ligands of the quinazoline family protect against glutamate induced glial cell death. Abstracts, ISFN 19th Annual Meeting, Eilat, 12-14 December 2010.
73. Haghighat N, McCandless DW, Geraminegad P. The effect of ammonium chloride on metabolism of primary neurons and neuroblastoma cells in vitro. Metab Brain Dis 2000; 15:151-162.
74. Veenman L, Gavish M. Peripheral-type benzodiazepine receptors: their implication in brain disease. Drug Dev Res 2000; 50:355-370.
75. Papadopoulos V, Lecanu L. Translocator protein (18 kDa) TSPO: an emerging therapeutic target in neurotrauma. Exp Neurol 2009; 219:53-57.
76. Kim CH, Chung HJ, Lee HK, Huganir RL. Interaction of the AMPA receptor subunit GluR2/3 with PDZ domains regulates hippocampal long-term depression. Proc Natl Acad Sci USA 2001; 98:11725-11730. (Pubitemid 32928796)
77. Carlisle HJ, Luong TN, Medina-Marino A, Schenker L, Khorosheva E, Indersmitten T, et al. Deletion of densin-180 results in abnormal behaviors associated with mental illness and reduces mGluR5 and DISC1 in the postsynaptic density fraction. J Neurosci 2011; 31:16194-16207.
78. Szydlowska K, Tymianski M. Calcium, ischemia and excitotoxicity. Cell Calcium 2010; 47:122-129.
79. Kanai Y, Hediger MA. The glutamate/neutral amino acid transporter family SLC1: molecular, physiological and pharmacological aspects. Pflugers Arch 2004; 447:469-479. (Pubitemid 38241433)
80. Torres GE, Amara SG. Glutamate and monoamine transporters: new visions of form and function. Curr Opin Neurobiol 2007; 17: 304-312. (Pubitemid 46880333)
81. Aoyama K, Wang F, Matsumura N, Kiyonari H, Shioi G, Tanaka K, et al. Increased neuronal glutathione and neuroprotection in GTRAP3-18-deficient mice. Neurobiol Dis 2012; 45:973-982.
82. Nakamura BN, Fielder TJ, Hoang YD, Lim J, McConnachie LA, Kavanagh TJ, Luderer U. Lack of maternal glutamate cysteine ligase modifier subunit (Gclm) decreases oocyte glutathione concentrations and disrupts preimplantation development in mice. Endocrinology 2011; 152:2806-2815.
83. Nagler R, Ben-Izhak O, Savulescu D, Krayzler E, Akrish S, Leschiner S, et al. Oral cancer, cigarette smoke and mitochondrial 18 kDa translocator protein (TSPO)-in vitro, in vivo, salivary analysis. Biochim Biophys Acta 2010; 1802:454-461.
84. Hardwick M, Fertikh D, Culty M, Li H, Vidic B, Papadopoulos V. Peripheraltype benzodiazepine receptor (PBR) in human breast cancer: correlation of breast cancer cell aggressive phenotype with PBR expression, nuclear localization, and PBR-mediated cell proliferation and nuclear transport of cholesterol. Cancer Res 1999; 59:831-842. (Pubitemid 29086736)
85. Brown RC, Degenhardt B, Kotoula M, Papadopoulous V. Location-dependent role of the human glioma cell peripheral-type benzodiazepine receptor in proliferation and steroid biosynthesis. Cancer Lett 2000; 156:125-132. (Pubitemid 30394669)
86. Mukhopadhyay S, Rajaratnam V, Mukherjee S, Das SK. Control of peripheral benzodiazepine receptor-mediated breast cancer in rats by soy protein. Mol Carcinog 2008; 47:310-319. (Pubitemid 351500157)
87. Furre IE, Shahzidi S, Luksiene Z, Møller MT, Borgen E, Morgan J, et al. Targeting PBR by hexaminolevulinate-mediated photodynamic therapy induces apoptosis through translocation of apoptosis-inducing factor (to the nucleus) in human leukemia cells. Cancer Res 2005; 65: 11051-11060. (Pubitemid 41713376)
88. Pretner E, Amri H, Li W, Brown R, Lin CS, Makariou E, et al. Cancer-related overexpression of the peripheral-type benzodiazepine receptor and cytostatic anticancer effects of Ginkgo biloba extract (EGb 761). Anticancer Res 2006; 26:9-22. (Pubitemid 43206054)
89. Alho H, Varga V, Krueger KE. Expression of mitochondrial benzodiazepine receptor and its putative endogenous ligand diazepam binding inhibitor in cultured primary astrocytes and C-6 cells: relation to cell growth. Cell Growth Differ 1994; 5:1005-1014. (Pubitemid 24275115)
90. Kuhlmann AC, Guilarte TR. Cellular and subcellular localization of peripheral benzodiazepine receptors after trimethyltin neurotoxicity. J Neurochem 2000; 74:1694-1704. (Pubitemid 30163992)